As Daiichi Sankyo looks to cement its place ... therapy veteran as its new global head of research and development. Ken Takeshita, M.D., will take up that position (PDF) from April 1, coming ...

Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed DXd antibody drug conjugate (ADC) patritumab deruxtecan, intended for ...

Daiichi Sankyo's head of global R&D, Ken Takeshita, said that EGFR-mutated NSCLC is known to be difficult to treat in the second-line metastatic setting, but added that the company is "conducting ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

“Our goal is to push the boundaries of science to change the way cancer is treated,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “These data reinforce the breadth and depth of ...

(RTTNews) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi ... said Ken Takeshita, Global Head ...

"Expanding our oncology pipeline with a DLL3 T-cell engager further supports Daiichi Sankyo’s strategy to create new standards of care for patients with cancer worldwide," said Ken Takeshita ...

Daiichi Sankyo has won Japanese approval for Ezharmia ... overcome the weakness of EZH2 blocking alone, global R&D chief Ken Takeshita, M.D., explained during an investor event in December.

1 “Expanding our oncology pipeline with a DLL3 T-cell engager further supports Daiichi Sankyo’s strategy to create new standards of care for patients with cancer worldwide,” said Ken Takeshita, MD, ...

Progress in Lung Cancer Across Daiichi Sankyo’s DXd ADC Portfolio Updated DATROWAY® (datopotamab deruxtecan) combination data across three early-phase trials will be highlighted in patients ...

Today we have Okuzawa, the Representative Director, President and COO; Ogawa of Executive Officer and CFO; and Takeshita ... results presentation for Daiichi Sankyo. We have announced FY 2023 ...